Good news emanating from late phase trials by development-stage firms is always refreshing for Prohost, especially when the news brings hope for the suffering patients whose diseases are not adequately responding to existing treatments.
Today GOOD news is coming from late Phase trials announcing that a product called Tenapanor has met all its Aprimary and secondary endpoints for irritable colon syndrome with constipation (IBS-C), which would support filing for approval in 2018. Tenapanor belongs to the late development-stage firm Ardelyx (ARDX), which reported positive results from its second Phase . . .